MORIMATSU INTL Reports Fiscal Year Results: Net Profit Declines 19.95% to 584 Million Yuan

Stock News

Yesterday

MORIMATSU INTL (02155) announced its annual financial results for the period ending December 31, 2025. The group recorded revenue of 6.955 billion yuan, a slight increase of 0.09% compared to the previous year. Net profit was 584 million yuan, representing a decrease of 19.95% year-on-year. Basic earnings per share were 0.49 yuan. The company stated that revenue from the pharmaceutical, biopharmaceutical, and daily chemical industries showed significant growth. The decline in revenue from certain other sectors was primarily attributed to a narrowing pace of expansion in downstream industries and a short-term slowdown in capital investment within Mainland China.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/news/1133305429"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1133305429\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1133305429?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-23 17:36","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1133305429","market":"hk","top_or_hot":-1,"title":"MORIMATSU INTL Reports Fiscal Year Results: Net Profit Declines 19.95% to 584 Million Yuan","media":"Stock News","content":"<p>MORIMATSU INTL (02155) announced its annual financial results for the period ending December 31, 2025. The group recorded revenue of 6.955 billion yuan, a slight increase of 0.09% compared to the previous year. Net profit was 584 million yuan, representing a decrease of 19.95% year-on-year. Basic earnings per share were 0.49 yuan. The company stated that revenue from the pharmaceutical, biopharmaceutical, and daily chemical industries showed significant growth. The decline in revenue from certain other sectors was primarily attributed to a narrowing pace of expansion in downstream industries and a short-term slowdown in capital investment within Mainland China.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>MORIMATSU INTL Reports Fiscal Year Results: Net Profit Declines 19.95% to 584 Million Yuan</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMORIMATSU INTL Reports Fiscal Year Results: Net Profit Declines 19.95% to 584 Million Yuan\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-03-23 17:36</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>MORIMATSU INTL (02155) announced its annual financial results for the period ending December 31, 2025. The group recorded revenue of 6.955 billion yuan, a slight increase of 0.09% compared to the previous year. Net profit was 584 million yuan, representing a decrease of 19.95% year-on-year. Basic earnings per share were 0.49 yuan. The company stated that revenue from the pharmaceutical, biopharmaceutical, and daily chemical industries showed significant growth. The decline in revenue from certain other sectors was primarily attributed to a narrowing pace of expansion in downstream industries and a short-term slowdown in capital investment within Mainland China.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1183","symbol_name":"工业机械","start_time":0,"source_url":"","article_id":"1133305429","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1133305429","pubTimestamp":1774258591,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"MORIMATSU INTL (02155) announced its annual financial results for the period ending December 31, 2025. The group recorded revenue of 6.955 billion yuan, a slight increase of 0.09% compared to the...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK1183":"工业机械","BK1548":"重型机械股","BK1587":"次新股","LU1171460220.USD":"FULLGOAL CHINA SMALL-MID CAP GROWTH \"A1\" (USD) INC","02155":"森松国际","LU2279858448.HKD":"富国中国中小盘成长基金 A1 类（港元）"},"translate_title":"森松国际公布财年业绩：净利润下降19.95%至5.84亿元","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02155":1},"content_text":"MORIMATSU INTL (02155) announced its annual financial results for the period ending December 31, 2025. The group recorded revenue of 6.955 billion yuan, a slight increase of 0.09% compared to the previous year. Net profit was 584 million yuan, representing a decrease of 19.95% year-on-year. Basic earnings per share were 0.49 yuan. The company stated that revenue from the pharmaceutical, biopharmaceutical, and daily chemical industries showed significant growth. The decline in revenue from certain other sectors was primarily attributed to a narrowing pace of expansion in downstream industries and a short-term slowdown in capital investment within Mainland China.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}